| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| USRE43390 | ALMIRALL | Pleuromutilin derivatives as antimicrobials |
Apr, 2021
(3 years ago) | |
| USRE39128 | ALMIRALL | Pleuromutilin derivatives as antimicrobials |
Apr, 2021
(3 years ago) | |
| US7875630 | ALMIRALL | Process salts compositions and use |
Feb, 2027
(2 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8207191 | ALMIRALL | Process, salts, composition and use |
Aug, 2024
(4 months from now) | |
Altabax is owned by Almirall.
Altabax contains Retapamulin.
Altabax has a total of 4 drug patents out of which 2 drug patents have expired.
Expired drug patents of Altabax are:
- USRE43390
- USRE39128
Altabax was authorised for market use on 12 April, 2007.
Altabax is available in ointment;topical dosage forms.
Altabax can be used as treatment of impetigo due to staphylococcus aureus or streptococcus pyogenes.
Drug patent challenges can be filed against Altabax from 13 April, 2011.
The generics of Altabax are possible to be released after 14 February, 2027.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Apr 12, 2012 |
Drugs and Companies using RETAPAMULIN ingredient
NCE-1 date: 13 April, 2011
Market Authorisation Date: 12 April, 2007
Treatment: Treatment of impetigo due to staphylococcus aureus or streptococcus pyogenes
Dosage: OINTMENT;TOPICAL
ALTABAX family patents
